Jan Garfinkle utilizes her educational background in biomedical engineering, extensive medical device operating experience and industry connections to select and nurture outstanding companies. Jan led Arboretum’s investment in HandyLab and served on the Board of Directors for five years until the company was acquired by Becton Dickinson. She has also led Arboretum’s investments in CardioMEMS, Uptake Medical, BAROnova, Vasonova, Esperion, NXThera, Life Magnetics and Sonitus Medical. She presently serves as a director of Accord Biosciences, NXThera, Life Magnetics, Sonitus and as a board observer on Uptake Medical, BAROnova, and Esperion. Jan heads the fundraising efforts at Arboretum and is a member of the Investment Committee. Jan founded the firm in 2002 and has been actively investing for eight years.
Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions within entrepreneurial healthcare companies. She worked for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI). Each of these companies was acquired by Eli Lilly for more than $100 million and became the foundation for Guidant Corporation. She joined each company early in its development and held key management roles in marketing, clinical research, and sales and successfully launched over 20 new medical products. She began her career as a manufacturing engineer and production line manager for Procter & Gamble.
Jan is the past President of the Michigan Venture Capital Association, an Advisory Board member of the Global Cardiovascular Innovation Center (GCIC) at the Cleveland Clinic, and a member of the Healthcare Advisory Board at the University of Michigan. Jan also serves as a member of AdvaMed’s National Venture Capital Advisory Board.
Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.